| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Zentiva was created through the merger of the Czech company, Léciva, and the
Slovak firm Slovakofarma, which was completed in August 2003. The two former
companies began selling products under the Zentiva name from the beginning of
September 2003. This report provides an insight into the company, reviewing
its current business structure and activities.
Zentiva specialises in the development of generics, and holds leading market
positions in both the Czech and Slovak Republics. Outside of these two home
markets, Zentiva's most important markets are those of Central and Eastern
Europe, and in particular the markets of Poland and Russia. The company is
establishing new businesses in other territories, including Lithuania, Latvia,
Bulgaria and Ukraine.
In October 2005, Zentiva announced its largest shareholder, Warburg Pincus
Funds, had sold 6.2 million shares in Zentiva at a price of CZK1,040 per share
(US$42.3), and a further 4.5 million shares at CZK1,025 per share (US$41.7
million). Following the sales, Warburg Pincus held just under 7.5 million
shares in Zentiva, representing around 20% of the issued share capital. The
movement in shares came as Zentiva celebrated its second anniversary, marking
the point at which Léciva merged with Slovakofarma.
In March 2006, Zentiva announced that sanofi-aventis had purchased a 25% stake
in the firm for 430.3 million euros (US$517.5 million). The stake included
19.6% of shares bought from Warburg Pincus, and represented all of Warburg's
interest in Zentiva. For more information, see the Major Developments section
of this report.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- Zentiva: Top Brands, 2005 (CZK millions)
- FINANCIAL RESULTS
- Latest Yearly Results
- Financial results, 1999 - 2005 (CZK millions)
- Pharmaceutical sales by region, 2004 - 2005 (CZK millions)
- Latest Quarterly Results
- Zentiva: fourth quarter 2005 results (CZK millions)
- Zentiva: third quarter 2005 results (CZK millions)
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- Litigation
- CONTACT DETAILS
|
